How much does Mulpleta (Lusutrombopag Tablets) Cost& price without insurance in China?
Mulpleta® is the commercial brand name of Lusutrombopag Tablets, developed by Shionogi Inc. It is an oral thrombopoietin receptor agonist. It selectively activates thrombopoietin receptors on bone marrow megakaryocytes to promote megakaryocyte proliferation and maturation, raising peripheral platelet counts and lowering perioperative bleeding risk for thrombocytopenic patients.
Main Indications
Perioperative platelet elevation treatment for chronic liver disease adult patients with thrombocytopenia who need to undergo elective invasive procedures.
Clinical Research
Global multicenter pivotal trials fully validated its platelet-boosting efficacy for cirrhotic patients;
Phase III registration trials confirmed oral short-cycle administration effectively increases platelet levels and reduces intraoperative transfusion demand;
Dose-finding comparative studies identified optimal treatment cycle with balanced efficacy and safety;
Long-term observational research showed low incidence of portal vein thrombosis under standard dosing;
Tolerability follow-up trials verified mild transient adverse reactions and controllable overall safety spectrum for short-course preoperative use.
Common Side Effects
Common mild adverse reactions: Headache, nausea, diarrhea, fatigue and peripheral edema;
Laboratory abnormalities: Rare transient mild elevation of liver enzymes;
Severe but uncommon risks: Portal vein thromboembolism, severe hypersensitivity responses and abnormal platelet overelevation.
Approval Status in China
Mulpleta® (specification 3mg per tablet, 7 tablets per box) obtained marketing approval in China in 2020. It is an oral prescription hematological drug included in China’s Category B medical insurance catalogue.
Buy Mulpleta (Lusutrombopag Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
